Dietary integration with galactose, Coenzyme Q and reduced glutathione healed low back pain: A case report

Isabella Panfoli* and Daniela Calzia
Dipartimento di Farmacia, Laboratorio di Biochimica, Università di Genova, Italy

Abstract
This paper deals with the case of a 79-year-old female patient presenting chronic low back pain secondary to total knee replacement 6 months before, to whom physical therapy had negligible effect. Score 10 on the leeds assessment of neuropathic symptoms and signs pain scale ruled out neurologic causes. A plain X-ray scan showed widespread signs of spondylosis, slight anteposition of L3, multiple lumbar discopathies, but no disk herniation. Physical examination, and assessment of Numeric Pain Rating Scale, were conducted during her initial visit, after six weeks and at 8-month follow-up. Treatment consisted of daily integration with two sub-tongue patented tablet containing: galactose (500mg), reduced glutathione (50 mg) and Coenzyme Q10 (50 mg) after evening meal. After 6 weeks of supplementation, back pain had disappeared, and all outcome measures were improvement.

*Correspondence to: Isabella Panfoli, MD, PhD - Biochemist University of Genova-DIFAR.le Benedetto XV, 316132 Genova, Italy, Tel: +390103537397; Fax: +390103538153; E-mail: panfoli@difar.unige.it

Key words: coenzyme Q10, galactose, low back pain, oxidative phosphorylation, neuroprotection

Received: September 28, 2018; Accepted: October 09, 2018; Published: October 12, 2018
an underlying herniated disk. Neurological sensory and motor testing was normal and symmetrical. Ankle clonus and Babinski reflex were not present. Absence of weight loss, night-time fever/ sweats, fatigue, pins and needles/ numbness in groin region, alterations to bladder and bowel function, allowed to exclude serious pathology [4] even though the patient had a history of cancer. There was evidence of significant sciatic nerve irritation. Blood and urine analyses were unremarkable. Due to the severity of symptoms but considering her allergy to main Nonsteroidal anti-inflammatory drugs her general practitioner had prescribed paracetamol (1 g x 2/ daily) with little effect.症状 persistence led to suspect the involvement of the intervertebral discs, causing compression to the sciatic nerve root and leg symptoms. As patient did not improve after 3 months of pharmacologic treatment, clinician considered addition of nonpharmacologic therapy namely spinal manipulation and rehabilitation, exercise therapy. It was recommended referral to physical therapy management with spinal manipulation therapy, with a physiotherapist, but this did not improve outcomes 6 months after symptom onset. Her pain has improved but not resolved. The patient was then referred to a local orthopedic consultant, specialist in spinal injury in Genoa. As LBP lasted more than 3 months it was considered chronic and was imaged. The clinician prescribed an X-Ray scan of the spine. Scan identified that the disc contents had not leaked out even though there were widespread signs of spondylosis with marginal osteophytosis, slight anteroposition of L3. The working diagnosis was a mild L3 dysfunction with involvement of sciatic nerve irritation. Based on this results, surgical procedure was not indicated. It was decided to follow the patient conservatively with follow-up in 6 weeks the physical exam mimicked what one would expect of a patient with a benign musculoskeletal condition.

Physical examination

**X-Ray Scan**

As reported in Figure 1, the most pertinent findings at the imaging X-ray scan were: double curved dorso-lumbar scoliosis. Partial rotation of metamers. Widespread signs of spondylosis with marginal osteophytic protrusions. Slight anteroposition of L3. Multiple lumbar discopathies. Diffuse degenerative discs in the middle and lower tract of the dorsal spine; osteoporotic spine, but no disk herniation.

**Diagnostic Focus and Assessment**

Physical examination, and assessment of Numeric Pain Rating Scale (NPRS), Oswestry Disability Index (ODI), and Pain Self -Efficacy Questionnaire (PSEQ), were conducted during her initial visit, after six weeks and at 8-month follow-up.

**Therapeutic Focus and Assessment and Timeline**

Treatment was designed to allow neuroprotection, considering that pain mechanism was essentially irritation of ischiatic nerve. The focus of the intervention was neuro-protective for the ischiatic nerve, with an oral daily integration with two substrate patented tablet containing: galactose (500mg), reduced glutathione (50 mg) and Coenzyme Q10 (50 mg) after evening meal. 6 weeks later, the patient reported dramatic change in her condition, as symptoms had disappeared. Treatment consisted of daily integration.

**Follow-up and Outcomes**

Outcome measures included the NPRS, ODI and PSEQ value. A score 10 on the Leeds assessment of neuropathic symptoms and signs pain scale allowed to rule out neuropathic mechanisms contributing to the patient’s pain. Therefore, Magnetic Resonance Imaging was not recommended. Six weeks after the beginning of oral integration, the patient’s NPRS,ODI, and PSEQ scores improved by more than 80% without any medication (Table 1).

**Discussion**

Authors report herein a patient presenting with low back pain. Normally LBP is caused by musculoskeletal reasons, and does not require particularly any intervention or treatment, but often damaged. Intervertebral discs are the cause of pain. In this case, pain can become chronic and the management of a patient with a chronic LBP and sometimes multiple health conditions can pose problems as far the clinical decision. Spinal manipulation can sometimes be effective, although it is unclear to what extent [6].

National guidelines are not in accordance as for the recommendation of manipulation or physical therapy [7], which is commonly adopted. Patients with low back pain must first be into one of three broad categories with accurate anamnestic and physical examination: nonspecific LBP, back pain potentially associated with radiculopathy or spinal stenosis, or back pain potentially associated with a sinister (when severe or progressive neurologic defects) are present or other specific spinal cause. Our case was placed in the second category. Accordingly, diagnostic imaging and testing was limited. Paracetamol is a first-line therapy for managing acute low back pain, as its efficacy is well established. Relief, in the case of our patient even though utilizing regular use of appropriate doses (1 g twice a day) only provided moderate relief. Patient did not utilize Nonsteroidal anti-inflammatory drugs, due to her allergy, even though their efficacy in low back pain is limited. Therefore, the patient was not envisaging any efficacious treatment. In fact, neuroprotection is considered not applicable, especially in these mild cases. In this context, we considered both our previous biochemical data and clinical results. The former showed that the mitochondrial F,F,-ATP synthase, and the respiratory complexes are expressed in myelin [8-13] which together with the axonal mitochondria, would supply the axoplasm with aerobically...
synthesized ATP, through connexons [14]. The latter is a case report which showed that dietary neuroprotecting daily integration with galactose (3g) and Coenzyme Q10 (100 mg) in a woman with a brain Magnetic Resonance Imaging showing periventricular and callosal multiple lesions suggestive of a demyelinating nature, allowed to delay the diagnosis of Multiple Sclerosis after three follow-up within 18 months now, regardless of the fact that patient’s condition was considered strongly suggestive of early Multiple Sclerosis.

In fact, d-galactose would play a role as a bioenergetics substrate for the extra-mitochondrial ATP synthesis and oxygen consumption in myelin. In fact, demyelinated axons eventually degenerate. It was supposed that d-galactose can become the substrate of hexose-6-phosphate dehydrogenase, whose functional expression was shown in isolated myelin which would be functionally associated to respiratory Complex I, expressed in myelin [15]. Hexose-6-phosphate dehydrogenase is a microsomal enzyme expressed in the endoplasmic reticulum, which has a particularly favorable K_m for galactose.

Galactose can enter the nerve cell across GLUT3, an hexose transporter which is not insulin-dependent [16]. Galactose can increment the oxidative burst in the cell. A beneficial effect of oral galactose was reported in preventing the development of the cognitive deficits in the streptozotocin-induced rat model of sporadic Alzheimer’s disease [17]. Along this view is the association with coenzyme Q10 for its function in funneling electrons through the electron transfer chain. It is also important to acknowledge that with the cited dietary integration the patient did not develop a worsening of her condition. In this respect, the integration with galactose/Coenzyme Q10, an approach intended support the myelin bioenergetics, may have exerted a neuroprotective effect, thereby reducing further insults to the white matter, thereby allowing the nerve to heal.

Notably, supplementation with galactose is recommendable, in the early stages of damage to nerves in order to support the other therapies in helping myelin to aerobically support the axon with chemical energy, which can accelerate healing.

Declaration of Interest

No potential conflict of interest was reported by the authors

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Table 1. Assessment of pain and disability

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>6 weeks</th>
<th>8 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRS</td>
<td>7</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>ODI</td>
<td>38</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>PSEQ</td>
<td>18</td>
<td>49</td>
<td>51</td>
</tr>
</tbody>
</table>

Table reports the assessment of pain and disability, before (baseline) and at the end (6 weeks) of the nutritional treatment and at a follow up after 8 months. NPRS Numerical rating Scale (range 0–10) ODI Oswestry Disability Index (range 0–100) and PSEQ Pain Self Efficacy Questionnaire (range 0–60) were evaluated.

References


